The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance
Chimeric antigen receptor T cell (CAR-T) therapies have shown unprecedented response rates and may extend survival for patients expected to live only a few more months. Now, CAR-T developers are looking at how to improve responses, extend survival and improve safety.
You may also be interested in...
Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.
Celgene will pay $9bn to buy the 90.3% of Juno that it doesn't already own, seeking to not only become a leader in the CAR-T field, but to increase its leadership in non-Hodgkin lymphoma, multiple myeloma, other hematological malignancies.
Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.